60.60
-0.08 (-0.13%)
| Penutupan Terdahulu | 60.68 |
| Buka | 60.72 |
| Jumlah Dagangan | 1,198,590 |
| Purata Dagangan (3B) | 1,765,085 |
| Modal Pasaran | 11,727,554,560 |
| Harga / Pendapatan (P/E TTM) | 404.00 |
| Harga / Pendapatan (P/E Ke hadapan) | 10.24 |
| Harga / Jualan (P/S) | 3.07 |
| Harga / Buku (P/B) | 3.48 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 28 Apr 2025 - 2 May 2025 |
| Margin Keuntungan | 0.77% |
| Margin Operasi (TTM) | 25.34% |
| EPS Cair (TTM) | 0.150 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 16.30% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 0.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.75% |
| Nisbah Semasa (MRQ) | 1.97 |
| Aliran Tunai Operasi (OCF TTM) | 335.34 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 619.45 M |
| Pulangan Atas Aset (ROA TTM) | 0.86% |
| Pulangan Atas Ekuiti (ROE TTM) | 0.75% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Incyte Corporation | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.70 |
|
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Core |
| % Dimiliki oleh Orang Dalam | 1.99% |
| % Dimiliki oleh Institusi | 96.77% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 92.00 (Guggenheim, 51.82%) | Pegang |
| Median | 74.50 (22.94%) | |
| Rendah | 65.00 (Morgan Stanley, 7.26%) | Pegang |
| Purata | 77.00 (27.06%) | |
| Jumlah | 1 Beli, 5 Pegang | |
| Harga Purata @ Panggilan | 63.96 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Morgan Stanley | 24 Mar 2025 | 65.00 (7.26%) | Pegang | 62.78 |
| Guggenheim | 18 Mar 2025 | 92.00 (51.82%) | Pegang | 60.00 |
| Truist Securities | 18 Mar 2025 | 72.00 (18.81%) | Pegang | 60.00 |
| Citigroup | 11 Feb 2025 | 88.00 (45.21%) | Beli | 66.33 |
| RBC Capital | 11 Feb 2025 | 68.00 (12.21%) | Pegang | 66.33 |
| 23 Jan 2025 | 70.00 (15.51%) | Pegang | 72.53 | |
| Stifel | 10 Feb 2025 | 77.00 (27.06%) | Pegang | 68.30 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| TROTTA MATTEO | - | 62.08 | -537 | -33,337 |
| Jumlah Keseluruhan Kuantiti Bersih | -537 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -33,337 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 62.08 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| TROTTA MATTEO | Pegawai | 25 Mar 2025 | Dibuang (-) | 537 | 62.08 | 33,337 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |